{
    "clinical_study": {
        "@rank": "163028", 
        "arm_group": [
            {
                "arm_group_label": "Study group", 
                "arm_group_type": "Experimental", 
                "description": "Weight-based dose (0.15 mg/kg for patients less than 38 kg, 8 mg for patients weighing 38-62 kg, or 12 mg for patients weighing greater than 62 kg) of methylnaltrexone will be administered on post-operative day 3 and again, if indicated, on post-operative day 4. This group will also receive the standard bowel protocol beginning on postoperative day one as per protocol."
            }, 
            {
                "arm_group_label": "Institutional bowel protocol", 
                "arm_group_type": "Active Comparator", 
                "description": "Patient will receive institutional standard bowel protocol. Beginning on post-operative day one either miralx,docusate sodium or senna, on a weight-based dose. If no bowel movement in 72 hours, either oral bisacodyl or magnesium hydroxide, on a weight-based dosing, will be added."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether the routine use of methylnaltrexone in the\n      post-operative pediatric spinal fusion patient will decrease the incidence of constipation."
        }, 
        "brief_title": "Methylnaltrexone Use for Opioid-induced Postoperative Constipation", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Constipation", 
        "condition_browse": {
            "mesh_term": "Constipation"
        }, 
        "detailed_description": {
            "textblock": "Methylnaltrexone will be given to pediatric patients post-operative from spinal fusion\n      surgery on post-operative day number 3 and then again on postoperative day number 4, if no\n      laxation achieved. Various outcome measures, safety and efficacy of the drug will be\n      observed and recorded."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  spinal fusion surgery\n\n          -  current opioid use\n\n          -  12 years of age and older\n\n          -  no or inadequate bowel movement by post-operative day 3\n\n        Exclusion Criteria:\n\n          -  known or expected mechanical bowel obstruction\n\n          -  known or suspected lesions of the GI tract\n\n          -  unexpected transfer to ICU\n\n          -  unexpected return to the operating room\n\n          -  patient or parent refusal of methylnaltrexone\n\n          -  incomplete data concerning time to laxation"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "21 Years", 
            "minimum_age": "12 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01773096", 
            "org_study_id": "MNTX-2013"
        }, 
        "intervention": [
            {
                "arm_group_label": "Study group", 
                "description": "Patient will receive methylnaltrexone on postoperative day 3 on a weight based dose and again 24 hours later if required.", 
                "intervention_name": "Methylnaltrexone", 
                "intervention_type": "Drug", 
                "other_name": "Relistor"
            }, 
            {
                "arm_group_label": [
                    "Study group", 
                    "Institutional bowel protocol"
                ], 
                "description": "Standard institutional bowel protocol will begin on post-operative day 1.  Miralax,Docusate sodium or senna will be given on a weight-based dosing. If no bowel movement in 72 hours, bisacodyl or magnesium hydroxide will be added.", 
                "intervention_name": "Senna, docusate sodium, bisacodyl, magnesium hydroxide, Miralax", 
                "intervention_type": "Drug", 
                "other_name": "Senokot,Colace, Dulcolax, Milk of Magnesia, polyethylene glycol"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Bisacodyl", 
                "Bismuth subsalicylate", 
                "Magnesium Hydroxide", 
                "Methylnaltrexone", 
                "Naltrexone", 
                "Analgesics, Opioid"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "opioid-induced", 
        "lastchanged_date": "May 17, 2013", 
        "location": {
            "contact": {
                "last_name": "Vermaire, M.D.", 
                "phone": "509-623-0428"
            }, 
            "contact_backup": {
                "last_name": "Charlotte Preuschoff", 
                "phone": "509-623-0427"
            }, 
            "facility": {
                "address": {
                    "city": "Spokane", 
                    "country": "United States", 
                    "state": "Washington", 
                    "zip": "99203"
                }, 
                "name": "Shriners Hospitals for Children- Spokane"
            }, 
            "investigator": {
                "last_name": "Deborah J. Vermaire, M.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Use of Methylnaltrexone to Reduce Post-operative Opioid-induced Constipation in the Pediatric Spinal Fusion Patient", 
        "other_outcome": {
            "measure": "time to oral intake of pediatric post-operative spinal fusion patient", 
            "safety_issue": "No", 
            "time_frame": "first post-operative week"
        }, 
        "overall_contact": {
            "email": "dvermaire@shrinenet.org", 
            "last_name": "Deborah J. Vermaire, M.D.", 
            "phone": "509-623-0428"
        }, 
        "overall_official": {
            "affiliation": "Shriners Hospitals for Children", 
            "last_name": "Deborah J. Vermaire, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "reduction of post-operative opioid induced constipation", 
            "safety_issue": "Yes", 
            "time_frame": "first post-operative week"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01773096"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Shriners Hospitals for Children", 
            "investigator_full_name": "Deborah J. Vermaire MD", 
            "investigator_title": "Anesthesiologist", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "results_reference": {
            "PMID": "21998076", 
            "citation": "Anissian L, Schwartz HW, Vincent K, Vincent HK, Carpenito J, Stambler N, Ramakrishna T. Subcutaneous methylnaltrexone for treatment of acute opioid-induced constipation: phase 2 study in rehabilitation after orthopedic surgery. J Hosp Med. 2012 Feb;7(2):67-72. doi: 10.1002/jhm.943. Epub 2011 Oct 13."
        }, 
        "secondary_outcome": {
            "measure": "time to ambulation in post-operative pediatric spinal fusion patients", 
            "safety_issue": "No", 
            "time_frame": "first post-operative week"
        }, 
        "source": "Shriners Hospitals for Children", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Shriners Hospitals for Children", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}